On June 29, 2021, Valeo Pharma Inc., a Canadian pharmaceutical company, announced the closing of its "bought deal" short form prospectus offering of 11,500,000 units for gross proceeds of C$11.5 million, including the full exercise of the underwriters' over-allotment option.
Research Capital Corporation acted as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Paradigm Capital Inc. and Desjardins Capital Markets.
Fasken advised Research Capital Corporation with a team led by John Sabetti, and included Daniel Fuke and Nazish Mirza.
Research Capital Corporation acted as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Paradigm Capital Inc. and Desjardins Capital Markets.
Fasken advised Research Capital Corporation with a team led by John Sabetti, and included Daniel Fuke and Nazish Mirza.
Jurisdiction
- Ontario
